ICH S13 Draft Guideline: The Well-Characterized ONT and Opportunities for Tailored Nonclinical Development
Free
- Length
- 1 hr
- Topic
- Medical & Clinical
About this webinar
Hosted by the SOT Biotechnology Specialty Section, Drug Discovery Toxicology Specialty Section, and Regulatory and Safety Evaluation Specialty Section
The draft ICH S13 guidance, Nonclinical Safety Evaluation of Oligonucleotide-Based Therapeutics, introduces a harmonized framework for the nonclinical development of ONTs. This webinar will provide a high-level overview of the guidance, with emphasis on the well-characterized ONT concept and opportunities to leverage prior knowledge to support more focused, efficient, and scientifically justified nonclinical programs. Additional discussion will highlight risk-based, WoE approaches, new approach methodologies, and other ONT-specific considerations that may enable more tailored development strategies. A panel of ICH S13 Expert Working Group members will discuss the draft guidance and address questions during a panel discussion and Q&A.
Speakers
Tod Harper, PhD, DABT, Scientific Director, Amgen
Xuan Chi, PhD, Supervisory Pharmacologist, US FDA
Jen Sisler, PhD, DABT, Director of Toxicology, Eli Lily